ResMed Valuation Overview

RMD -- USA Stock  

USD 115.33  0.17  0.15%

ResMed holds recent Real Value of $97.2157 per share. The prevailing price of the company is $115.33. At this time the company appears to be over valued. Macroaxis determines value of ResMed from analyzing the company fundamentals such as Shares Outstanding of 142.5M, Operating Margin of 29.63% and Return On Equity of 16.97% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support investing in undervalued entities and to dispose of overvalued entities since at some point stocks prices and their ongoing real values will merge together.
Investments

Valuation Drivers Correlation

Click cells to compare fundamentals   View All Correlations
ResMed Valuation Data Drivers
Net Income Per Employee    Enterprise Value    Market Capitalization    

ResMed Market Cap

ResMed is rated below average in market capitalization category among related companies. Market capitalization of Medical Instruments & Supplies industry is at this time estimated at about 203.51 Billion. ResMed holds roughly 16.43 Billion in market capitalization claiming about 8% of all equities under Medical Instruments & Supplies industry.
Capitalization  Revenue  Total debt  Valuation  Workforce
Horizon     30 Days    Login   to change
ResMed is rated below average in five year return category among related companies. It is rated below average in price to book category among related companies fabricating about  4.81  of Price to Book per Five Year Return.

Current Market Valuation

ResMed Valuation Boundaries

Over Valued
December 14, 2018
115.33
Market Value
97.22
Real Value
Target Odds
  
126.86
Upside
ResMed is not too risky asset. Calculation of real value of ResMed is based on 2 months time horizon. Increasing ResMed time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.

Valuation Basics

ResMed Enterprise Value Fundamentals

Quick Ratio1.68
Earnings Quarterly Growth22.80%
Revenue Growth12.30%
Payout Ratio61.21%
Enterprise Value To Ebitda22.41
Earnings Growth21.70%
Enterprise Value To Revenue6.64
Additionally take a look at Your Equity Center. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Search macroaxis.com